ArticleWorld journal of surgical oncology2022
Clinicopathological characteristics and outcomes of malignant adenomyoepithelioma of the breast: a single institution's experience.
Article in World journal of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Malignant adenomyoepithelioma of the breast with contralateral homologous tumor and ductal carcinomaInternational journal of surgery case reports · 2026Article
- Malignant adenomyoepithelioma withOncology letters · 2026Article
- Malignant breast adenomyoepithelioma with diagnostic discordance: a case report and literature review.Frontiers in oncology · 2026Article
- Malignant adenomyoepithelioma of the breast: a rare case report and literature review.Journal of surgical case reports · 2026Article
- Triple-Negative Breast Cancer Coexisting with Adenomyoepithelioma: A Case Report.Journal of the Korean Society of Radiology · 2026Article
- Malignant adenomyoepithelioma of the breast with axillary metastasis: a case report in a patient undergoingFrontiers in oncology · 2026Article
- Malignant adenomyoepithelioma of the breast with axillary lymph node metastasis: a case report and review of the literature.Frontiers in oncology · 2025Article
- Can Epithelial-Myoepithelial Carcinoma of the Breast Benefit from TROP2 Antibody-Drug Conjugate?OncoTargets and therapy · 2025Article
- Benign Adenomyoepithelioma of the Breast: A Case Report and Review of Imaging Features.Cureus · 2024Article
- A rare case of a recurrent atypical adenomyoepithelial tumor of the breast: Case report.International journal of surgery case reports · 2023Article
- Malignant adenomyoepithelioma of the breast: cases report and literature review.American journal of translational research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalignant adenomyoepithelioma of the breast is a rare tumor and most of relevant literature consists of individual case reports. This study objective was designed to evaluate clinicopathological features and treatment outcomes of 15 cases of malignant adenomyoepithelioma at a single institute.
methodsA retrospective medical record review was performed for 15 subjects confirmed with malignant adenomyoepithelioma upon postoperative pathological diagnosis at the Asan Medical Center from January 2008 to June 2018. Data regarding age at diagnosis, preoperative biopsy results, operation methods, the status of hormone receptors and HER2, and clinical outcomes were collected.
resultsAll cases were female patients diagnosed at median age of 50 years. Preoperative core needle biopsy results showed that 40% of the cases (6 out of 15) were benign which was in discordance with the final malignant pathology report. Thirteen cases underwent wide excision with or without sentinel lymph node biopsy (SLNB) and 2 cases had total mastectomy with SLNB. Five of 11 cases (45.5%) were triple negative. Ten of 15 cases underwent postoperative radiation therapy, 3 cases underwent chemotherapy, and 5 cases underwent endocrine therapy. During median follow-up of 55 months, the 5-year overall survival rate was 87.5% and the 5-year disease free survival rate was 91.7%. Two lung metastases developed. One case showed local recurrence 3 years after surgery and radiotherapy and subsequently developed lung metastasis 1 year late. Another case developed lung metastasis one and a half years after surgery in combination with endocrine therapy and neoadjuvant chemotherapy.
conclusionPreoperative core needle biopsy showed inaccurate results for diagnosing malignant adenomyoepithelioma. Malignant adenomyoepithelioma has a high rate of triple negative subtype but has a relatively good prognosis although there is a risk of local and systemic recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.